1. Home
  2. CCCC vs TWN Comparison

CCCC vs TWN Comparison

Compare CCCC & TWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

N/A

Current Price

$3.14

Market Cap

404.7M

Sector

Health Care

ML Signal

N/A

TWN

Taiwan Fund Inc. (The)

N/A

Current Price

$101.74

Market Cap

550.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CCCC
TWN
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
404.7M
550.8M
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
CCCC
TWN
Price
$3.14
$101.74
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $13.33
N/A
AVG Volume (30 Days)
★ 1.8M
19.7K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 16.45
N/A
EPS
N/A
★ N/A
Revenue
★ $35,947,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 1.02
N/A
52 Week Low
$1.69
$51.37
52 Week High
$5.17
$108.83

Technical Indicators

Market Signals
Indicator
CCCC
TWN
Relative Strength Index (RSI) 43.53 56.08
Support Level $2.88 $94.56
Resistance Level $3.91 $103.42
Average True Range (ATR) 0.18 3.26
MACD 0.01 -0.09
Stochastic Oscillator 57.04 66.11

Price Performance

Historical Comparison
CCCC
TWN

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

About TWN Taiwan Fund Inc. (The)

Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.

Share on Social Networks: